同义名 :	(R)-(+)-Etomoxir
	CAS号 :	124083-20-1
	货号 :	A482603
	分子式 :	C17H23ClO4
	纯度 :	99%+
	分子量 :	326.82
	MDL号 :	MFCD11227266
	存储条件：	Pure form Inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-

生物活性

描述

Etomoxir irreversibly binds to the catalytic site of carnitine palmitoyltransferase-1 (CPT-1) on the outer mitochondrial membrane, inhibiting its activity and reducing fatty acid transport into mitochondria. Besides acting as a CPT-1 inhibitor, Etomoxir also functions as a peroxisomal proliferator in the liver, promoting DNA synthesis and liver growth, which suggests it might also act as a PPARalpha agonist[1]. As a member of the oxirane carboxylic acid group, Etomoxir is recognized for its potential as a therapeutic for heart failure. Acute treatment with Etomoxir irreversibly inhibits CPT-1, leading to reduced mitochondrial fatty acid β-oxidation, accumulation of cytosolic fatty acids, and enhanced glucose oxidation. Extended exposure (24 hours) to Etomoxir affects the expression of various metabolic enzymes, indicating diverse metabolic impacts[2].

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	3.06mL 0.61mL 0.31mL	15.30mL 3.06mL 1.53mL	30.60mL 6.12mL 3.06mL

参考文献

[1]Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36. [2]Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003 Feb;44(2):415-23. [3]Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724. [4]Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419(2):447-55.